Detailed explanation of the treatment cycle and drug cost of neratinib/neratinib

Neratinib/Neratinib is a kinase inhibitor for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. It specifically binds to HER2, HER4 and other receptors and blocks the growth and proliferation signals transmitted by these receptors, thereby effectively curbing the proliferation of cancer cells.

For patients with early-stage HER2-positive breast cancer, the standard treatment regimen for neratinib is 240 mg daily for a full year, unless the disease relapses. For advanced or metastatic breast cancer, neratinib is used in combination with capecitabine, administered daily, every 21 days as a cycle, and capecitabine is given at the same time for the first 14 days. As long as the condition does not worsen and the side effects are tolerable, the treatment will continue.

The common packaging specification of neratinib on the market is 40mg*180 tablets per box. Based on the recommended dose of 240 mg per day, one box of neratinib can supply the patient's treatment needs for approximately one month. Of course, this is based on the premise that the patient continues to take the medication and does not adjust the dose due to side effects and other reasons.

Regarding drug prices, the original drug neratinib has been launched in many places around the world and has been partially included in the medical insurance system. in the country, the price of each box of neratinib is about RMB 7,000. In overseas markets, each box of neratinib may cost more than 10,000 US dollars, which is significantly higher. Fortunately, there are also generic drug options of neratinib on the market. These drugs are basically the same in ingredients as the original drug, but at a more affordable price. For example, the price of a box of generic neratinib produced by Bangladesh Yaopin International is only about more than 2,000 yuan, providing patients with a more economical treatment option (the price may fluctuate due to factors such as exchange rates).